WebOperating Status Active. Last Funding Type Post-IPO Debt. Legal Name Cytokinetics, Inc. Stock Symbol NASDAQ:CYTK. Company Type For Profit. Contact Email [email protected]. Phone Number 6506243010. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and … WebAug 4, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. Net loss for the second...
Cytokinetics Reports First Quarter 2024 Financial Results
WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2024 was $389.0 million or $4.33 per share. WebFeb 6, 2014 · Financial Guidance 2014. Cytokinetics also announced its financial guidance for 2014. The company anticipates cash revenue will be in the range of $19 to $21 million, cash R&D expenses will be in ... chronicle characters
Estimating The Fair Value Of Cytokinetics, Incorporated ... - Yahoo Finance
WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential … WebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated … WebMay 6, 2024 · SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $47.1 million, or $0.66 per share, compared to net loss for the first quarter of 2024 of $39.4 million, or $0.66 per share. chronicle children\u0027s books